ArticleAntimicrobial agents and chemotherapy2017
Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid.Antimicrobial agents and chemotherapy · 2020Trial
- Biotope-dependent resistance to reactive oxygen species, antibiotic tolerance, and virulence of Staphylococcus aureus.Communications biology · 2026Article
- Host-driven remodelling of theMicrobiology (Reading, England) · 2026Review
- Fatty acid synthase in high and low lipid-producing strains of Mucor circinelloides: identification, phylogenetic analysis, and expression profiling during growth and lipid accumulation.Biotechnology letters · 2025Article
- Treatment ofAntimicrobial agents and chemotherapy · 2025Article
- Prophages divert Staphylococcus aureus defenses against host lipids.Journal of lipid research · 2024Article
- An inhibitory mechanism of AasS, an exogenous fatty acid scavenger: Implications for re-sensitization of FAS II antimicrobials.PLoS pathogens · 2024Article
- Oxidative stress is intrinsic to staphylococcal adaptation to fatty acid synthesis antibiotics.iScience · 2024Article
- Article
- Lipid-Centric Approaches in Combating Infectious Diseases: Antibacterials, Antifungals and Antivirals with Lipid-Associated Mechanisms of Action.Antibiotics (Basel, Switzerland) · 2023Review
- A small-molecule membrane fluidizer re-sensitizes methicillin-resistantAntimicrobial agents and chemotherapy · 2023Article
- Chlorhexidine Resistance or Cross-Resistance, That Is the Question.Antibiotics (Basel, Switzerland) · 2023Review
- FabT, a Bacterial Transcriptional Repressor That Limits Futile Fatty Acid Biosynthesis.Microbiology and molecular biology reviews : MMBR · 2022Review
- Type II Fatty Acid Synthesis Pathway and Cyclopropane Ring Formation Are Dispensable during Enterococcus faecalis Systemic Infection.Journal of bacteriology · 2021Article
- Branched chain fatty acid synthesis drives tissue-specific innate immune response and infection dynamics of Staphylococcus aureus.PLoS pathogens · 2021Article
- Article
- Article
- Article
- A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production.Antimicrobial agents and chemotherapy · 2019Article
- Staphylococcus aureus Utilizes Host-Derived Lipoprotein Particles as Sources of Fatty Acids.Journal of bacteriology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need for new antimicrobials to treat bacterial infections has led to the use of type II fatty acid synthesis (FASII) enzymes as front-line targets. However, recent studies suggest that FASII inhibitors may not work against the opportunist pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.